In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Will New Drugs For Motor Symptoms Of Parkinson's Disease Deliver?

Executive Summary

Because of the severity of the disease and the unmet medical need, competition to develop more effective treatments for motor complications of Parkinson's disease is fierce. Biopharma companies are employing a variety of strategies including reformulating approved drugs via new delivery systems and developing first-in-class therapies, which although riskier scientifically may command higher prices and greater acceptance from payors.
Advertisement

Related Content

Parkinson’s Disease At A Crossroad: Deals And Emerging Therapeutics
Building the New Generation of Drugs in Neurodegeneration
Building the New Generation of Drugs in Neurodegeneration

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003678

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel